Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 3.96
BIOC's Cash to Debt is ranked higher than
52% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. BIOC: 3.96 )
Ranked among companies with meaningful Cash to Debt only.
BIOC' s 10-Year Cash to Debt Range
Min: 0  Med: 2.65 Max: No Debt
Current: 3.96
Equity to Asset 0.65
BIOC's Equity to Asset is ranked higher than
58% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BIOC: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
BIOC' s 10-Year Equity to Asset Range
Min: -18.63  Med: -0.03 Max: 0.83
Current: 0.65
-18.63
0.83
Z-Score: -7.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -5489.41
BIOC's Operating margin (%) is ranked lower than
96% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. BIOC: -5489.41 )
Ranked among companies with meaningful Operating margin (%) only.
BIOC' s 10-Year Operating margin (%) Range
Min: -1227100  Med: -10033.68 Max: -5928.36
Current: -5489.41
-1227100
-5928.36
Net-margin (%) -5701.96
BIOC's Net-margin (%) is ranked lower than
96% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.26 vs. BIOC: -5701.96 )
Ranked among companies with meaningful Net-margin (%) only.
BIOC' s 10-Year Net-margin (%) Range
Min: -1362900  Med: -11588.52 Max: -6890.3
Current: -5701.96
-1362900
-6890.3
ROE (%) -220.66
BIOC's ROE (%) is ranked lower than
92% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.76 vs. BIOC: -220.66 )
Ranked among companies with meaningful ROE (%) only.
BIOC' s 10-Year ROE (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -220.66
ROA (%) -117.23
BIOC's ROA (%) is ranked lower than
92% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.65 vs. BIOC: -117.23 )
Ranked among companies with meaningful ROA (%) only.
BIOC' s 10-Year ROA (%) Range
Min: -694.81  Med: -659.50 Max: -400.76
Current: -117.23
-694.81
-400.76
ROC (Joel Greenblatt) (%) -2843.97
BIOC's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. BIOC: -2843.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3222.72  Med: -2717.73 Max: -1614.63
Current: -2843.97
-3222.72
-1614.63
» BIOC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.80
BIOC's P/B is ranked higher than
59% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. BIOC: 2.80 )
Ranked among companies with meaningful P/B only.
BIOC' s 10-Year P/B Range
Min: 2.1  Med: 3.39 Max: 5.65
Current: 2.8
2.1
5.65
P/S 79.33
BIOC's P/S is ranked lower than
96% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.22 vs. BIOC: 79.33 )
Ranked among companies with meaningful P/S only.
BIOC' s 10-Year P/S Range
Min: 8.02  Med: 34.46 Max: 110
Current: 79.33
8.02
110
Current Ratio 9.07
BIOC's Current Ratio is ranked higher than
89% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BIOC: 9.07 )
Ranked among companies with meaningful Current Ratio only.
BIOC' s 10-Year Current Ratio Range
Min: 0.02  Med: 4.13 Max: 10.2
Current: 9.07
0.02
10.2
Quick Ratio 8.98
BIOC's Quick Ratio is ranked higher than
90% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. BIOC: 8.98 )
Ranked among companies with meaningful Quick Ratio only.
BIOC' s 10-Year Quick Ratio Range
Min: 0.02  Med: 3.99 Max: 10.09
Current: 8.98
0.02
10.09
Days Inventory 24.41
BIOC's Days Inventory is ranked higher than
77% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.61 vs. BIOC: 24.41 )
Ranked among companies with meaningful Days Inventory only.
BIOC' s 10-Year Days Inventory Range
Min: 9.26  Med: 12.06 Max: 23.71
Current: 24.41
9.26
23.71
Days Sales Outstanding 22.90
BIOC's Days Sales Outstanding is ranked higher than
92% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.88 vs. BIOC: 22.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOC' s 10-Year Days Sales Outstanding Range
Min: 24.51  Med: 46.91 Max: 1825
Current: 22.9
24.51
1825

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.18
BIOC's Price/Net Cash is ranked higher than
84% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.85 vs. BIOC: 3.18 )
Ranked among companies with meaningful Price/Net Cash only.
BIOC' s 10-Year Price/Net Cash Range
Min: 2.99  Med: 4.17 Max: 4.78
Current: 3.18
2.99
4.78
Price/Net Current Asset Value 2.94
BIOC's Price/Net Current Asset Value is ranked higher than
83% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.23 vs. BIOC: 2.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIOC' s 10-Year Price/Net Current Asset Value Range
Min: 2.77  Med: 3.75 Max: 4.12
Current: 2.94
2.77
4.12
Price/Tangible Book 2.80
BIOC's Price/Tangible Book is ranked higher than
69% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.15 vs. BIOC: 2.80 )
Ranked among companies with meaningful Price/Tangible Book only.
BIOC' s 10-Year Price/Tangible Book Range
Min: 2.64  Med: 3.38 Max: 3.88
Current: 2.8
2.64
3.88
Price/Median PS Value 2.51
BIOC's Price/Median PS Value is ranked lower than
90% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. BIOC: 2.51 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOC' s 10-Year Price/Median PS Value Range
Min: 0.42  Med: 0.70 Max: 2.61
Current: 2.51
0.42
2.61
Earnings Yield (Greenblatt) (%) -53.50
BIOC's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. BIOC: -53.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -560.3  Med: 0.00 Max: 0
Current: -53.5
-560.3
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:B00.Germany,
» More Articles for NAS:BIOC

Headlines

Articles On GuruFocus.com
mbs Feb 24 2015 
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 

More From Other Websites
Dr. Marileila Varella Garcia Joins Biocept as Scientific Advisor Aug 03 2015
Dr. Marileila Varella Garcia Joins Biocept as Scientific Advisor Aug 03 2015
Biocept Announces Presentation at Next Generation Dx Summit Jul 30 2015
Biocept Announces Presentation at Next Generation Dx Summit Jul 30 2015
Biocept (BIOC) Stock Gains After Launching Melanoma Diagnostic Assay Jul 14 2015
Tuesday's Mid-Day Movers: Iran's Nuclear Deal Reached; Micron Technology Bid, Box Inc And More Jul 14 2015
Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma Jul 14 2015
Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma Jul 14 2015
Biocept Announces Panel Presentation at Cantor Fitzgerald Healthcare Conference Jul 06 2015
Biocept Announces Panel Presentation at Cantor Fitzgerald Healthcare Conference Jul 06 2015
Biocept (BIOC) Stock Soaring After Expanding Blood-Based Test Menu Jul 01 2015
BUZZ-U.S. STOCKS ON THE MOVE-Teladoc, Comstock, Peabody, WPCS Jul 01 2015
BUZZ-U.S. STOCKS ON THE MOVE-Chubb, Teladoc, CalAmp, Chambers Street Jul 01 2015
BUZZ-U.S. STOCKS ON THE MOVE-Chubb, Xenon Pharma, Ballard Power Jul 01 2015
BUZZ-U.S. STOCKS ON THE MOVE-Chubb, Tetralogic Pharma, Ballard Power Jul 01 2015
BUZZ-U.S. STOCKS ON THE MOVE-Chubb, Constellation Brands, Biocept Jul 01 2015
Biocept Expands Blood-Based Test Menu to Identify Key Biomarker for Breast Cancer and Non-Small Cell... Jul 01 2015
BIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 17 2015
Biocept Enters Clinical Collaboration with Sarah Cannon Research Institute Focused on Screening ER+... Jun 03 2015
Biocept Granted U.S. Patent for Blood Collection and Transport Tube Jun 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK